Ginkgo bioworks and xprescheck receive award to expand cdc's traveler-based sars-cov-2 genomic surveillance program in u.s. airports

Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurity boston and new york , aug. 15, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna) and xpresspa group, inc. (nasdaq: xspa) announced they will continue to support the centers for disease control and prevention's (cdc's) traveler-based sars-cov-2 genomic surveillance program through a new contract awarded august 12, 2022. the partnership is expected to support public health and biosecurity services totaling approximately $16 million, with an overall potential to exceed $61 million based on cdc program options and public health priorities.
DNA Ratings Summary
DNA Quant Ranking